Kyoto University Center for iPS Cell Research and Application has transferred a new chimeric antigen receptor (CAR) T-cell therapy derived from induced pluripotent stem cells (iPSCs) to Takeda for Phase I clinical trial. Terms Under the terms of their collaborative...